ReviewCellular and molecular life sciences : CMLS2011
Beyond natural antimicrobial peptides: multimeric peptides and other peptidomimetic approaches.
Review in Cellular and molecular life sciences : CMLS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed.
- In silico design and In Vitro validation of WK15: a promising antimicrobial peptide for aquaculture applications.World journal of microbiology & biotechnology · 2026Article
- Addressing antimicrobial resistance: Current challenges, emerging strategies, and an AI-powered, community-driven approach.PNAS nexus · 2026Review
- Brilacidin's Antifungal Mechanism: Insights from Lipid Membrane Models.Antibiotics (Basel, Switzerland) · 2026Article
- Short Synthetic Lipopeptides CAntibiotics (Basel, Switzerland) · 2026Article
- Polyacrylamide-Based Antimicrobial Copolymers to Replace or Rescue Antibiotics.ACS central science · 2025Article
- Exploring Tryptophan-based Short Peptides: Promising Candidate for Anticancer and Antimicrobial Therapies.Anti-cancer agents in medicinal chemistry · 2025Article
- Aggression to Biomembranes by Hydrophobic Tail Chains under the Stimulus of Reductant.Molecules (Basel, Switzerland) · 2024Article
- Antimicrobial Peptides and Their Biomedical Applications: A Review.Antibiotics (Basel, Switzerland) · 2024Review
- Peptide Dendrimer-Based Antibacterial Agents: Synthesis and Applications.ACS infectious diseases · 2024Review
- Treatment of MRSA Infection: Where are We?Current medicinal chemistry · 2024Review
- The Expression of Antibacterial Peptide Turgencin A inMolecules (Basel, Switzerland) · 2023Article
- Biological Function of Antimicrobial Peptides on Suppressing Pathogens and Improving Host Immunity.Antibiotics (Basel, Switzerland) · 2023Review
- Characterizing the Interactions of Cell-Membrane-Disrupting Peptides with Lipid-Functionalized Single-Walled Carbon Nanotubes.ACS applied materials & interfaces · 2023Article
- Effects of Dimerization, Dendrimerization, and Chirality in p-BthTX-I Peptide Analogs on the Antibacterial Activity and Enzymatic Inhibition of the SARS-CoV-2 PLPharmaceutics · 2023Article
- Glycopolymers for Antibacterial and Antiviral Applications.Molecules (Basel, Switzerland) · 2023Review
- Article
- S100 Proteins as Novel Therapeutic Targets in Psoriasis and Other Autoimmune Diseases.Molecules (Basel, Switzerland) · 2022Review
- Heterogeneous-Backbone Proteomimetic Analogues of Lasiocepsin, a Disulfide-Rich Antimicrobial Peptide with a Compact Tertiary Fold.ACS chemical biology · 2022Article
- Multitalented Synthetic Antimicrobial Peptides and Their Antibacterial, Antifungal and Antiviral Mechanisms.International journal of molecular sciences · 2022Review
- Antimicrobial Peptide Dendrimers and Quorum-Sensing Inhibitors in Formulating Next-Generation Anti-Infection Cell Therapy Dressings for Burns.Molecules (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Naturally occurring antimicrobial peptides (AMPs) present several drawbacks that strongly limit their development into therapeutically valuable antibiotics. These include susceptibility to protease degradation and high costs of manufacture. To overcome these problems, researchers have tried to develop mimics or peptidomimetics endowed with better properties, while retaining the basic features of membrane-active natural AMPs such as cationic charge and amphipathic design. Protein epitope mimetics, multimeric (dendrimeric) peptides, oligoacyllysines, ceragenins, synthetic lipidated peptides, peptoids and other foldamers are some of the routes explored so far. The synthetic approach has led to compounds that have already entered clinical evaluation for the treatment of specific conditions, such as Staphylococcus (MRSA) infections. Should these trials be successful, an important proof-of-concept would be established, showing that synthetic oligomers rather than naturally occurring molecules could bring peptide-based antibiotics to clinical practice and the drug market for local and systemic treatment of medical conditions associated with multi-drug resistant pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.